16
Participants
Start Date
January 15, 2024
Primary Completion Date
September 30, 2025
Study Completion Date
April 30, 2026
Sodium propionate
"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
Placebo
"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
RECRUITING
Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité-Universitätsmedizin Berlin, Berlin
University Hospital Heidelberg
OTHER
University Hospital, Essen
OTHER
University Hospital of Cologne
OTHER
Universitätsklinikum Hamburg-Eppendorf
OTHER
Charite University, Berlin, Germany
OTHER